Microbot Medical Boosts C-Suite Compensation, Awards CEO Special Bonus
MBOT has more than doubled off its 52-week low of $1.25 on elevated volume (3.4× avg).
Summary
Microbot Medical Inc. announced increased salaries and bonus potential for its CTO, CFO, and CMO, alongside a $140,000 special bonus for its CEO, signaling a focus on executive retention and motivation.
Key Events · Executive and Board Changes · MBOT
-
CTO Compensation Increased
Simon Sharon, Chief Technology Officer, received an increase in annual base salary to NIS 1,008,000 and an increase in maximum annual bonus potential to 50% of base salary, effective for the 2026 fiscal year.
-
CFO Compensation Increased
Rachel Vaknin, Chief Financial Officer, received an increase in annual base salary to NIS 756,000 and an increase in maximum annual bonus potential to 50% of base salary, effective for the 2026 fiscal year.
-
CMO Bonus Potential Increased
Dr. Juan Diaz-Cartelle, Chief Medical Officer, had his maximum annual bonus potential increased to 50% of base salary, effective for the 2026 fiscal year.
-
CEO Awarded Special Bonus
Harel Gadot, Chief Executive Officer, President, and Chairman, was authorized to receive a special bonus of approximately $140,000.
Analysis · MBOT · Industrial Applications And Services
This filing details significant compensation adjustments for Microbot Medical's key executives, including increased base salaries for the CTO and CFO, higher maximum annual bonuses for the CTO, CFO, and CMO, and a special bonus for the CEO. These changes, effective for the 2026 fiscal year, signal the company's commitment to retaining and incentivizing its leadership team. While the direct financial impact of the CEO's bonus is modest relative to the company's market capitalization, the broad-based adjustments across the C-suite suggest confidence in the executive team's ongoing contributions and future performance.
At the time of this filing, MBOT was trading at $2.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $170.6M. The 52-week trading range was $1.25 to $4.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.